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ABSTRACT
Uterine leiomyomas are benign soft-tissues tumors that arise from uterine smooth muscle tissue. 
Etiopathogenesis of leiomyomas is not well understood. We aimed to examine whether antioxidant enzyme 
activities and lipid hydroperoxides level in patients with leiomyoma are influenced by changes in sex 
hormones and gonadotropins (estradiol (E2), progesterone, FSH, and LH) during menstrual cycle and in 
postmenopause. The material consisted of blood and uterine tissue specimens. Hormone concentrations 
were determined and assays for superoxide dismutase, catalase, glutathione peroxidase and glutathione 
reductase activities and lipid hydroperoxides concentration were performed. In blood of examined women, 
a significant difference in catalase, glutathione peroxidase and glutathione reductase activity was recorded 
among the phases. There was also a positive correlation between the estradiol/progesterone concentration 
and the catalase activity. Progesterone negatively correlated with lipid hydroperoxides level. In myoma 
tissue, we recorded a phase-related difference in lipid hydroperoxides level and activities of superoxide 
dismutase, glutathione peroxidase activities, and glutathione reductase. Negative correlation was observed 
between FSH and glutathione peroxidase. The results suggest that antioxidant status in patients with uterine 
leiomyoma is influenced by the changes in sex hormones during the menstrual cycle and in postmenopause, 
indicating a role of the observed relationship in the leiomyoma etiology.
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INTRODUCTION
Uterine leiomyomas are benign soft-tissues 
tumors that arise from uterine smooth muscle 
tissue (myometrium) and they are also called 
myomas or uterine fibroids. As non-cancerous 
growth arising from myometrium, leiomyomas 
are unrelated to the common forms of uterine 
cancer and uterine cervical cancer which typically 
arise from the endometrium (the uterine lining) 
or cervical epithelium, respectively. Currently, 
the pathogenesis and etiology of leiomyomas are 
not well understood but several risk factors have 
been identified. These include early menarche 
(<10 years of age), nulliparity, age, hypertension, 
obesity, multiple uterine infections, tamoxifen use 
and ethnicity (Flake et al. 2003). Many studies 
are in agreement that African-American women 
present 2-3 times greater leiomyoma incidence 
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than Caucasian, Asian or Hispanic women, 
as well as significantly higher serum levels of 
estrone (E1), estradiol (E2) and free E2 (Blake 
2007). Some associations have been suggested 
with elevated levels of fibrotic growth factors 
and vascular abnormalities (Weintraub and Yemin 
2011). Protective factors have also been identified, 
including smoking, multiparity, menopause, 
progestin-only injectable contraceptives, and oral 
contraceptive pills (Houston et al. 2001, Wallach 
and Vlahos 2004).
The growth of uterine leiomyomas is considered 
to be influenced by estrogen (E2), growth hormone, 
and progesterone. Such dependence is indicated by 
the fact that most of these tumors are diagnosed 
during the reproductive years when they exhibit 
maximum growth, and regress after menopause 
(Evans and Brunsell 2007). Many investigations 
also indicated differences between non-transformed 
and leiomyoma tissue concentrations of estrogens 
and progesterone and their respective receptors 
(ER-α, ER-β and PR-A, PR-B) (Ciavattini et al. 
2013). Leiomyomas may occasionally increase 
in size during pregnancy, which can be caused by 
hormones, but also by increased blood flow and 
edema (Wallach and Vlahos 2004).
Reactive oxygen species (ROS) have many 
physiological regulatory functions and are also 
implicated in the development of a wide spectrum 
of diseases (Alfadda and Sallam 2012). The 
mammalian cell has an adequate antioxidant 
system to cope with excessive ROS production 
under normal physiological conditions. This 
system consists of antioxidant (AO) vitamins, thiol-
containing compounds such as reduced glutathione 
(GSH), and antioxidant enzymes, including 
superoxide dismutase (SOD), catalase (CAT), 
glutathione peroxidase (GPx) and glutathione 
reductase (GR). Variations in antioxidant capacity 
may influence individual susceptibility to some 
diseases associated with the deleterious effects of 
oxidative reactions (Shinde et al. 2012).
The relationship between sex hormones 
and antioxidant system was investigated during 
regular cyclic changes of endometrium, and in 
the reproductive system disorders. SOD plays an 
important role in maintaining luteal cell integrity 
and steroidogenic capacity (Sugino and Kato 1994) 
and its expression in endometrial stromal cells is 
associated with decidualization (Sugino et al. 2000). 
In amenorrheic women, estradiol but not progestagen 
replacement therapy stimulated erythrocyte GPx 
activity (Massafra et al. 2000). It is believed that 
estrogen decreases free radical production, and 
depressed estrogen synthesis in postmenopausal 
women is responsible for enhanced oxidative stress 
(Agarwal et al. 2005). In endometrial cells of women 
with endometriosis, Andrade et al. (2013) reported 
elevated levels of H2O2 and lower CAT activity, along 
with antiapoptotic effect of estradiol (E2), increased 
cell proliferation and increased mitogen-activated 
protein kinase (ERK) phosphorylation. These results 
support the findings of high endogenous oxidative 
stress in endometriotic cells due to alterations of 
ROS detoxification pathways and activation of 
ERK1/2, similar to tumor cells (Ngô et al. 2009).
We have previously shown that antioxidant status 
is altered in patients with endometrial hyperplasia or 
adenocarcinoma in comparison to women diagnosed 
with polyp or leiomyoma (Pejić et al. 2008, 2009). 
The aim of this study was to examine whether AO 
enzyme activities and lipid hydroperoxides (LOOH) 
level in patients with uterine leiomyoma are influenced 
by changes in sex hormones during the menstrual 
cycle and in postmenopause.
MATERIALS AND METHODS
SUBJECTS
The material used in this study consisted of 30 
blood and tissue specimens of women admitted to 
the Department of Gynecology and Obstetrics for 
gynecological evaluation within routine checkups 
or for abnormal uterine bleeding (Metrorrhagia 
prolongata, Metrorrhagia recidivans, Metrorrhagia 
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postmenopausi). They were diagnosed with uterine 
leiomyoma, confirmed by histopathological 
findings. Study was conducted prospectively and 
it was approved by the Human Studies Ethics 
Committee of the Clinical Center. The protocol 
was consistent with the World Medical Association 
Declaration of Helsinki (Ethical Principles for 
Medical Research Involving Human Subjects). All 
specimens were taken after obtaining the informed 
consent and none of the subjects had undergone 
hormone therapy or any other medical treatment in 
the last 6 months. Patients were divided as follows: 
11 in the follicular phase (F) (age, 39-49 yr; median 
45 yr), 10 in the luteal phase (L) (age, 37-50 yr; 
median 44 yr), 9 in the postmenopause (PM) (age, 
51-70 yr, median 56 yr).
SAMPLES
Venous blood samples were collected into heparinized 
tubes on the same day of uterine biopsy and aliquoted 
immediately. For SOD assay (OxisResearch™), blood 
was centrifuged at 2500 g for 5 min. Plasma was 
discarded and pellet was resuspended in 4 packed-cell 
volume of ice-cold demineralized ultrapure water 
(MilliQ reagent grade water system, Millipore Corp., 
Bedford, MA, USA). After addition of ethanol/
chloroform extraction reagent (62.5/37.5 vol/
vol) to remove hemoglobin interference, samples 
were centrifuged at 3000 g for 10 min (Eppendorf 
centrifuge 5417, Eppendorf AG, Hamburg, 
Germany). Upper aqueous layer was collected and 
kept at -70 °C until assay.
Myoma samples were washed in saline solution 
and homogenized in phosphate buffer containing 
0.05M KH2PO4 and 1 mM EDTA, pH 7.8 (1 g tissue per 
2 ml buffer) in a Teflon/glass homogenizer (Spindler 
and Hoyer, Göttingen, Germany) and frozen at -70 °C 
for 20 h in order to disrupt cell membranes. For SOD 
assay (OxisResearch™), thawed homogenates were 
vortexed 1 min and centrifuged at 8600 g, for 20 min 
at 4 °C (Eppendorf centrifuge 5417, Eppendorf AG, 
Hamburg, Germany). According to manufacturer’s 
recommendation, after addition of ethanol/chloroform 
extraction reagent (62.5/37.5 vol/vol) to completely 
remove hemoglobin interference, samples were 
centrifuged at 6000 g for 20 min, at 4 °C (Beckman 
centrifuge J2-21, Beckman Instruments Inc., Palo 
Alto, CA, USA). Upper aqueous layer was collected 
and kept at -70 °C until assay. The enzyme activities 
and lipid hydroperoxide (LOOH) concentration were 
monitored spectrophotometrically (Perkin Elmer 
Spectrophotometer, Lambda 25, Perkin Elmer Instru-
ments, Norwalk, CT, USA).
The specific enzyme activities were expressed 
as Units (U) or mU per milligram of total cell 
protein (U or mU/mg protein). LOOH concentration 
was expressed as nmol/mg protein. Determination 
of protein concentration was performed in tissues 
homogenates by the method of Lowry et al. 
(1951) and expressed as mg/ml. Plasma follicle-
stimulating hormone (FSH), luteinizing hormone 
(LH), estradiol (E2) and progesterone (P) levels 
were analyzed using standard radioimmunoassay 
(RIA) methods by the hormone analysis laboratory.
ASSAYS
ASSAY OF SOD ACTIVITY
Determination of total SOD activity was performed 
using Oxis Bioxytech® SOD-525™ Assay (Oxis 
International, Inc., Portland, OR, USA). The method 
is based on SOD-mediated increase of autoxidation 
of 5,6,6a11b-tetrahydro-3,9,10-tryhydroxybenzo[c]
fluorene in aqueous alkaline solution to yield a 
chromophore with maximum absorbance at 525 nm. 
The SOD activity is determined from the ratio of the 
autoxidation rates in the presence (Vs) and in the 
absence (Vc) of SOD. One SOD-525 activity unit is 
defined as the activity that doubles the autoxidation 
rate of the control blank.
ASSAY OF CAT ACTIVITY
CAT activity was determined by the method 
of Beutler (1982). The reaction is based on the 
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rate of H2O2 degradation by catalase, contained 
in the examined samples. The reaction was 
performed in an incubation mixture containing 
1M Tris-HCl, 5mM EDTA, pH 8.0, and monitored 
spectrophotometrically at 230 nm. One unit of CAT 
activity is defined as 1 µmol of H2O2 decomposed 
per minute under the assay conditions.
ASSAY OF GPX ACTIVITY
GPx activity was assessed using the Oxis 
Bioxytech® GPx-340™ Assay (Oxis International, 
Inc., Portland, OR, USA), based on the principle 
that oxidized glutathione (GSSG) produced 
upon reduction of an organic peroxide by GPx, 
is immediately recycled to its reduced form 
(GSH) with concomitant oxidation of NADPH 
to NADP+. The oxidation of NADPH was 
monitored spectrophotometrically as a decrease 
in absorbance at 340 nm. One GPx-340 unit is 
defined as 1 µmol of NADH oxidized per minute 
under the assay conditions.
ASSAY OF GR ACTIVITY
Activity of GR was measured using the Oxis 
Bioxytech® GR-340™ Assay (Oxis International, 
Inc., Portland, OR, USA). Assay is based on 
the oxidation of NADPH to NADP+ during 
the reduction of oxidized glutathione (GSSG), 
catalyzed by a limiting concentration of 
glutathione reductase. The oxidation of NADPH 
was monitored spectrophotometrically as a 
decrease in absorbance at 340 nm. One GR-340 
unit is defined as 1 µmol of NADH oxidized per 
minute under the assay conditions.
LIPID HYDROPEROXIDES
Concentration of LOOH was measured by 
Oxis Bioxytech® LPO-560™ Assay (Oxis 
International, Inc., Portland, OR, USA), which 
is based on the ability of hydroperoxides to react 
with an excess of Fe2+ at a low pH when the 
xylenol orange (XO) dye is present. The amount 
of Fe3+ generated by this reaction is measured as 
the Fe-XO complex at 560 nm, as demonstrated 
by the following equations:
Fe2+ + ROOH → Fe3+ + OH- + RO•
Fe3+ + XO → Fe-XO• (dye)
Since hydrogen peroxide content in many 
biological samples is much higher than that of 
other hydroperoxides, samples were pretreated 
with catalase to decompose the existing H2O2 and 
eliminate the interference.
STATISTICS
Statistical analysis was carried out with the use 
of the Kruskal-Wallis test and the Dunn’s post 
hoc test, which considered the unequal and small 
sample sizes we used in this study. A linear 
regression model was used to evaluate associations 
between hormonal and antioxidant variables. 
Before plotting the data in the regression study, the 
normality test on the variables was performed and 
the values of estradiol and progesterone were 
log-transformed. The 95% confidence intervals 
(CIs) for the regression lines were calculated. 
Two-tailed p values are given throughout. All data 
were analyzed using GraphPad Prism software.
RESULTS
The phase related concentrations of gonadotropins 
and sex hormones are reported in Table I. Significant 
changes were observed in FSH (H=8.63, p<0.05, 
Kruskal-Wallis) and in estradiol concentrations 
(H=6.74, p<0.05, Kruskal-Wallis).
ANTIOXIDANT PARAMETERS AND CORRELATION STUDY WITH 
SEX HORMONES IN BLOOD
The phase related changes of LOOH concentrations 
and AO enzyme activities in the blood of 
examined patients are shown in the Figure 1. The 
LOOH concentration and SOD activity were not 
significantly different with respect to the phase. 
The activity of CAT varied significantly (H=6.17, 
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p<0.05, Kruskal-Wallis) and it was lower in 
postmenopause than in luteal phase (p<0.05, 
Dunn test). GPx and GR showed significant 
changes of enzyme activities from F phase toward 
postmenopause (H=6.36, H=6.83, respectively 
p<0.05, Kruskal-Wallis). The activities of both 
enzymes were higher in postmenopause than in 
F phase (p<0.05, Dunn test).
Figure 1 - Changes in LOOH concentrations and AO enzyme activities in follicular phase (F), luteal phase (L) and postmenopause 
(PM) in blood of patients with uterine leiomyoma. Data are shown as mean ± SEM. P values refer to the results of the Dunn test.
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The linear regression analysis of individual 
hormonal variables against antioxidant parameters in 
blood (Fig. 2) showed significant positive correlation 
between the estradiol concentration and CAT activity 
(r=0.62, p<0.05), progesterone concentration and 
CAT activity (r=0.74, p<0.01), as well as a negative 
correlation between progesterone and LOOH 
concentrations (r=-0.65, p<0.05). No significant 
correlations were found between other hormones 
and antioxidant variables.
ANTIOXIDANT PARAMETERS AND CORRELATION STUDY WITH 
SEX HORMONES IN TISSUE
The phase related changes of LOOH concentrations 
and AO enzyme activities in uterine leiomyoma 
of examined patients are shown in Figure 3. 
Differently from the blood pattern, the LOOH 
concentration significantly differed with respect 
to the phase (H=6.68, p<0.05, Kruskal-Wallis). 
In follicular phase, it was significantly lower than 
in postmenopause (p<0.05, Dunn test) but not in 
comparison to the L phase.
The activity of SOD was significantly 
different (H=7.48, p<0.05, Kruskal-Wallis), and it 
was higher in luteal phase in comparison to both, 
follicular phase and postmenopause (p<0.05, 
Dunn test). The activity of CAT was stable, while 
the activities of GPx and GR varied significantly 
(H=6.78; H=7.12, p<0.05, respectively, Kruskal-
Wallis). Furthermore, the activities of both GPx 
and GR were significantly higher in luteal phase 
than in postmenopause (p<0.05, Dunn test).
The linear regression analysis of hormone 
levels and the examined AO parameters in uterine 
leiomyoma tissue (Fig. 4) showed negative 
correlation between FSH level and GPx activity 
(r= -0.64, p<0.01). No significant correlations 
were found between other hormones and anti-
oxidant variables.
DISCUSSION
This study shows the changes of AO enzymes 
activities and LOOH level in blood and uterine 
leiomyoma tissue of cycling women, and women in 
postmenopause. In the blood of these patients, we 
found no difference in LOOH concentration and 
SOD activity. The CAT activity was lower in the 
postmenopause than in the luteal phase and GPx and 
GR activities were higher in the postmenopause than 
in F phase. As in healthy women (Burger et al. 2007), 
patients with fibroids examined in this study, also 
had a decline of estradiol level in the postmenopause 
compared to women with regular cycle. At higher 
concentrations estradiol has some antioxidant 
properties while its decline in postmenopause is 
associated with pro-oxidant effects. These effects 
Follicular phase Luteal phase Postmenopause
FSH (U/L)*
Median
(Min/Max)
12.94±2.20
10.80
(7.80-20.10)
4.23±1.35
4.10
(1.90-6.80)
29.95±0.95
29.95
(29.00-30.90)
LH (U/L)
Median
(Min/Max)
4.62±1.57
3.10
(2.20-10.70)
2.00±1.24
0.95
(0.40-5.70)
5.75±2.25
5.75
(3.50-8.00)
Estradiol (pg/ml)*
Median
(Min/Max)
50.05±10.65
58.55
(18.50-64.60)
245.70±22.98
234.00
(213.00-290.00)
25.43±10.70
20.30
(10.00-46.00)
Progesterone (nmol/L)
Median
(Min/Max)
6.58±2.26
5.00
(1.60-14.70)
13.63±8.85
5.70
(3.00-40.10)
1.05±0.05
1.05
(1.00-1.10)
TABLE I
Changes in hormone levels during follicular phase, luteal phase and 
in postmenopause (Data are expressed as mean ± SEM; * p<0.05).
An Acad Bras Cienc (2015) 87 (3)
1777ANTIOXIDANT STATUS AND SEX HORMONES IN LEIOMYOMA
include oxidation of bases and formation of DNA 
adducts (Doshi and Agarwal 2013).
Studies of healthy women and those with 
hormonal and ovarian disorders provided different 
results about the influence of sex hormones on AO 
enzymes activity during menstrual cycle. Bednarek-
Tupikowska et al. (2001) found no significant 
differences of SOD activity in erythrocytes of 
healthy premenopausal and postmenopausal 
women. During the menstrual cycle, Massafra et al. 
(2000) observed no cycle-phase dependent changes 
in SOD and CAT activities as well as no correlation 
between activities of these enzymes and FSH, LH, 
estradiol or progesterone concentrations. Women 
with polycystic ovary syndrome were found to 
have higher SOD activity in blood than healthy 
women (Sabuncu et al. 2001). In women with 
ovulatory and anovulatory menstrual cycles it was 
observed that non-ovulating women had lower 
plasma 17-beta-estradiol concentrations than 
the ovulating ones, in both follicular and luteal 
phase, while the progesterone concentration was 
lower only in the luteal phase (Lutosłavska et al. 
2003). They also found higher SOD activity in 
non-ovulating women and no difference in CAT, 
GPx and GR activities in both groups of women 
with respect to the phase of the menstrual cycle. 
In ovulating women, inverse correlation was 
demonstrated between circulating estradiol and 
SOD activity (Lutosłavska et al. 2003).
In leiomyoma tissue, we observed similar 
pattern of SOD, GPx and GR activities, which were 
lower in the F phase and in the postmenopause than 
in the L phase. Furthermore, the elevated level of 
LOOH was recorded in postmenopause. Decreased 
activity of antioxidant enzymes, along with changes 
Figure 2 - Linear regression line and 95% CI to study the relationship between log Es/Pr and CAT activity, log Pr and LOOH 
concentration in the blood of patients with uterine leiomyoma.
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Figure 3 - Changes in LOOH concentrations and AO enzyme activities in follicular phase (F), luteal phase (L) and postmenopause 
(PM) in uterine leiomyoma tissue. Data are shown as mean ± SEM. P values refer to the results of the Dunn test.
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of hormones and lipid peroxides level, indicate that 
postmenopausal women are particularly sensitive 
to peroxidative stress. Based on current data, GPx 
was shown to be influenced by hormones. In women 
with amenorrhea, Massafra et al. (1996, 1997) 
found that estradiol treatment, but not progestogen, 
stimulates GPx activity in erythrocytes of these 
patients. In addition, the increased activities of 
GPx and CAT in erythrocytes were observed during 
extended use of oral contraceptives (Massafra et 
al. 1993, 1996). Healthy women with a normal 
ovulatory cycle manifested changes in the activity 
of GPx depending on the phase of the cycle, so the 
activity of this enzyme was higher in the late stage 
of the F phase in comparison to the earlier L phase 
(Massafra et al. 1998, 2000). There was a positive 
correlation between serum estradiol and changes in 
GPx activity relative to the phase of the menstrual 
cycle (Massafra et al. 2000, Bednarek-Tupikowska 
et al. 2001). Similar results regarding GPx activity 
in healthy women with regular cycles were 
obtained by Serviddio et al. (2002). The activity of 
this enzyme increased in the follicular phase and 
decreased in the luteal phase. These authors also 
showed a positive correlation between the activity 
of GPx and LH concentrations in healthy women.
In this study, we found inverse correlation 
between GPx and FSH level in leiomyoma tissue. In 
the blood of the examined women, CAT activity was 
positively correlated with estradiol and progesterone, 
while LOOH concentration was inversely correlated 
to progesterone. Reports suggested a connection 
between CAT activity and estrogen exposure. 
Castanho et al. (2012) reported antagonizing effect 
of hormone therapy on CAT activity in menopausal 
women, while results of Vaishali et al. (2005) 
indicated higher CAT activity and lower GPx activity 
in blood of premenopausal women, compared with 
those in postmenopause. The relation we observed 
might indicate that leiomyoma patients have certain 
specificity in which although CAT activity is lower, 
GPx activity is still elevated to cope with a free 
radical production in blood, even in postmenopause. 
In addition to estrogen levels, cellular redox state 
may also influence CAT activity. It was observed 
that long-term oxidative stress reduces stability and 
half-life of catalase by stimulating ubiquitination 
and proteosomal degradation of the enzyme (Cao et 
al. 2003). However, in maintenance of cellular H2O2 
levels, the harmonized CAT and GPX activity is 
most important since H2O2 plays an important role 
in many physiological processes like cell cycle and 
proliferation (Li et al. 2009), regulation of enzyme 
activity (Ferrer-Sueta et al. 2011), redox signalling 
(Sies 2014) and apoptosis (Andrade et al. 2013).
The role of progesterone in lipid peroxidation 
and AO body's defence is not clarified. Different 
results have been obtained, mainly as a consequence 
of progesterone preparations for hormone 
replacement therapy in postmenopausal women. 
Tranquilli et al. (1995) showed that treatment with 
medroxyprogesterone (MPA), whether used alone 
or in combination with estradiol, has antioxidant 
effects. On the other hand, Bednarek-Tupikowska 
et al. (2004) did not show the antioxidant effect 
of progesterone, because MPA in combination 
with estradiol, as part of hormone therapy, did 
not increase the observed antioxidant effect of 
estradiol. Negative correlation between the levels 
of progesterone and LOOH that we recorded 
Figure 4 - Linear regression line and 95% CI to study the 
relationship between log FSH and GPx activity in uterine 
leiomyoma tissue.
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in patients with fibroids could also indicate the 
antioxidant properties of progesterone.
Some data suggest a greater impact of progeste-
rone on the growth of uterine leiomyoma (Rein 2000), 
compared to estrogen, although others emphasize 
the role of estradiol (Barbarisi et al. 2001, Kovács et 
al. 2001) or of both steroids (Neuwirth and Moritz 
2008). It is still unclear how estradiol and progesterone 
affect the growth and development of fibroids since 
during pregnancy there is a decrease in the size of 
fibroids, when circulating levels of these hormones 
are high (Strobelt et al. 1994). Recent studies suggest 
that progesterone exerts a dualistic, stimulatory and 
inhibitory, effect on cell survival and growth of fibroids, 
depending on local growth factors surrounding these 
tissues (Maruo et al. 2004). It is also believed that 
sex steroids promote development of leiomyomas 
by stimulating inappropriate expression of growth 
factors. Estrogen and progesterone act as physiologic 
regulators of gene expression by activating nuclear 
receptors that are, themselves, transcription factors. In 
this way estrogen and progesterone play a key role in 
regulating genes that direct cell growth (Neuwirth and 
Moritz 2008). Studies already supported a role of these 
hormones in leiomyoma growth through a feedback 
mechanisms and activation of MAP-kinase pathways 
(Yu et al. 2010).
It was also observed that the agonist-
gonadotropin releasing hormone (GnRH) inhibits 
steroidogenesis and induces pharmacological 
menopause. Through this mechanism, GnRH can 
reduce fibroid volume by 50% within 3-6 months 
(Wang et al. 2002, Maruo et al. 2004). Clinical 
evidence of sex steroids involvement in leiomyoma 
growth can be seen with the shrinkage of leiomyoma 
during menopause and after GnRH administration 
in hypoestrogenic and hypoprogesterone states 
(Neuwirth and Moritz 2008).
The pathogenesis of uterine leiomyoma is still 
not clarified. Although all women of reproductive 
age experience significant exposure to estrogen, it is 
unclear what renders some individuals susceptible 
to leiomyoma formation. Our study suggests that 
in blood and uterine leiomyoma tissue, some AO 
enzymes are regulated by sex hormones. Whether 
the relation between endometrial AO status and 
changes of sex hormones level plays a role in its 
etiology, remains to be evaluated.
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RESUMO
Leiomiomas uterinos são tumores benignos dos tecidos 
moles que surgem da musculatura lisa uterina. A etiopa-
togênese dos leiomiomas não é bem compreendida. 
Nós objetivamos examinar se a atividade de enzimas 
antioxidantes e o nível de hidroperóxidos de lipídios 
em pacientes com leiomioma são influenciados por 
mudanças nos hormônios sexuais e nas gonadotropinas 
(estradiol (E2), progesterona, FSH e LH) durante 
o ciclo menstrual e na pós-menopausa. O material 
consistiu em sangue e espécimes de tecido uterino. 
As concentrações hormonais foram determinadas e 
foram realizados ensaios de atividade de superóxido 
dismutase, catalase, glutationa peroxidase e glutationa 
redutase e a concentração de hidroperóxidos de 
lipídios foi mensurada. No sangue das mulheres 
examinadas, foi verificada uma diferença significativa 
entre as fases nas atividades de catalase, glutationa 
peroxidase e glutationa redutase. Também houve 
uma correlação positiva entre a concentração de 
estradiol/progesterona e a atividade de catalase. A 
progesterona correlacionou negativamente com níveis 
de hidroperóxidos de lipídios. No tecido do mioma, 
foi verificada uma diferença relacionada à fase nos 
níveis de hidroperóxidos de lipídios e nas atividades 
de superóxido dismutase, glutationa peroxidase e 
glutationa redutase. Uma correlação negativa foi obser-
vada entre FSH e glutationa peroxidase. Os resultados 
sugerem que o estado antioxidante em pacientes com 
leiomioma uterino é influenciado por mudanças nos 
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hormônios sexuais durante o ciclo menstrual e na pós-
menopausa, indicando um papel da relação observada 
na etiologia do leiomioma.
Palavras chave: enzimas antioxidantes, hidroperóxidos 
de lipídios, esteroides sexuais, leiomioma.
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